Introducing Ritonavir-Boosted Nirmatrelvir (Paxlovid) at the National Center for Global Health and Medicine: Surveys Following its Introduction

Background: Paxlovid, an oral COVID-19 drug, is a ritonavir-containing drug, and as it significantly affects the activities of various drug-metabolizing enzymes, drug-drug interactions (DDIs) are a significant concern during clinical use of the drug. However, there are few reports on the observation...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Kansenshogaku Zasshi 2023/07/20, Vol.97(4), pp.125-135
Hauptverfasser:	SHIGENO, Ayako, OHASHI, Yasukata, MASUI, Ryosuke, KIRYU, Ayako, NAGASHIMA, Koji, OHASHI, Hirotake, SETO, Keisuke, MASUDA, Junichi, TERUYA, Katsuji, UJIIE, Mugen, OHMAGARI, Norio, NISHIMURA, Takahiro
Format:	Artikel
Sprache:	eng ; jpn
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!